See the DrugPatentWatch profile for Dupixent
Dupixent (dupilumab) has been approved for several indications since its initial launch.
When was Dupixent first approved?
The U.S. Food and Drug Administration (FDA) first approved Dupixent on March 28, 2017, for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies [1].
What other conditions is Dupixent approved for?
Dupixent's approval history extends to several other conditions:
* Adolescent Atopic Dermatitis: In 2017, it was also approved for adolescents aged 12 to 17 years with moderate-to-severe atopic dermatitis [1].
* Asthma: The FDA approved Dupixent for moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma in October 2018 [2].
* Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP): In June 2019, Dupixent received approval for CRSwNP as an add-on treatment in adults and adolescents aged 12 and older whose disease is inadequately controlled [3].
* Eosinophilic Esophagitis (EoE): In May 2022, Dupixent was approved for the treatment of adults and children aged 12 years and older, weighing at least 88 pounds (40 kg), with eosinophilic esophagitis [4].
* Prurigo Nodularis (PN): In September 2022, Dupixent was approved for the treatment of adults and children aged 6 years and older with prurigo nodularis [5].
* Pediatric Asthma: In June 2020, it received approval for children aged 6 to 11 years with moderate-to-severe atopic dermatitis [1]. In October 2023, it was approved for children aged 6 to 11 years with moderate-to-severe asthma [2].
What is the mechanism of action for Dupixent?
Dupixent is a monoclonal antibody that inhibits the signaling of two key cytokines, interleukin-4 (IL-4) and interleukin-13 (IL-13), which are central to the type 2 inflammation seen in conditions like atopic dermatitis, asthma, CRSwNP, EoE, and PN [1, 2, 3, 4, 5]. By blocking these cytokines, Dupixent helps to reduce inflammation [1].
What is the patent exclusivity timeline for Dupixent?
The patent protection for Dupixent is a critical factor for its market exclusivity. Information on specific patent expiry dates can be found on resources that track drug patents. According to DrugPatentWatch.com, details regarding the patent landscape and potential market entry for generics are available [6].
What are the key competitors for Dupixent?
Competitors vary depending on the specific indication. For atopic dermatitis, other biologics and topical treatments are available. In asthma and CRSwNP, Dupixent competes with other biologic agents targeting different inflammatory pathways. For EoE and PN, it represents a significant advancement with fewer directly comparable treatment options currently available, although the landscape is evolving.
What are the clinical trial results supporting Dupixent's approvals?
The approvals for each indication are based on data from extensive clinical trials. For atopic dermatitis, studies like SOLO 1 and SOLO 2 demonstrated significant improvements in skin clearing and reduction in itch [1]. Asthma trials, such as those for the eosinophilic phenotype, showed reductions in exacerbations and improvements in lung function [2]. Similar rigorous trial designs have underpinned the approvals for CRSwNP, EoE, and PN [3, 4, 5].
What are patient concerns regarding Dupixent?
Patient concerns often revolve around the effectiveness of the treatment for their specific condition, potential side effects such as injection site reactions or conjunctivitis, and the logistics of self-injection [1, 2, 3, 4, 5]. Cost and insurance coverage are also common considerations for patients.
Sources:
[1] https://www.drugpatentwatch.com/drug/dupilumab/atopic-dermatitis
[2] https://www.drugpatentwatch.com/drug/dupilumab/asthma
[3] https://www.drugpatentwatch.com/drug/dupilumab/chronic-rhinosinusitis-with-nasal-polyposis
[4] https://www.drugpatentwatch.com/drug/dupilumab/eosinophilic-esophagitis
[5] https://www.drugpatentwatch.com/drug/dupilumab/prurigo-nodularis
[6] https://www.drugpatentwatch.com/